Shares of Cartesian Therapeutics rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year. Shares were up 29% to $8.81 in Monday afternoon ...

What are the most pressing global crises in 2026? Each year, the International Rescue Committee’s (IRC) Emergency Watchlist identifies the countries at greatest risk of new or worsening humanitarian ...

One idle evening last October, Mehtaab Sawhney took up an old pastime. He began perusing the website erdosproblems.com, an updated record of the 1,179 conjectures left behind by the eccentric and ...

Investors might want to bet on Cartesian Therapeutics, Inc. (RNAC), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...

Artificial Intelligence 'I violated every principle I was given': AI agent deletes company's entire database in 9 seconds, then confesses Cancer New AI model spots pancreatic cancer up to 3 years ...

Community driven content discussing all aspects of software development from DevOps to design patterns. The speed and efficiency of traditionally developed software applications is limited by the fact ...

The busy box that is your brain is hard at work all day long—and it doesn’t quit when you’re asleep. Not only does your brain fill your slumber with dreams, it also goes right on solving the problems ...

Sven, a sales leader, received a call from a major customer who was furious. Their order arrived late, the product was damaged, and to top it off, their invoice didn’t reflect the volume discount ...

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...

NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation III (the “Company”) announced today the closing of its initial public offering of 27,600,000 units, including 3,600,000 units pursuant to the ...